P Magni
Overview
Explore the profile of P Magni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tosca E, Ronchi D, Rocchetti M, Magni P
AAPS J
. 2024 Aug;
26(5):92.
PMID: 39117850
Tumor volume doubling time (TVDT) has been shown to be a potential surrogate marker of biological tumor activity. However, its availability in clinics is strongly limited due to ethical and...
2.
Zucca S, Nicora G, De Paoli F, Carta M, Bellazzi R, Magni P, et al.
Hum Genet
. 2024 Mar;
PMID: 38520562
Identifying disease-causing variants in Rare Disease patients' genome is a challenging problem. To accomplish this task, we describe a machine learning framework, that we called "Suggested Diagnosis", whose aim is...
3.
Ronchi D, Tosca E, Bartolucci R, Magni P
J Pharmacokinet Pharmacodyn
. 2023 Jul;
51(2):109-121.
PMID: 37493851
Covariate identification is an important step in the development of a population pharmacokinetic/pharmacodynamic model. Among the different available approaches, the stepwise covariate model (SCM) is the most used. However, SCM...
4.
Strollo F, Gentile S, Pipicelli A, Mambro A, Monici M, Magni P
Front Bioeng Biotechnol
. 2022 Jun;
10:868999.
PMID: 35646861
During space flight, especially when prolonged, exposure to microgravity results in a number of pathophysiological changes such as bone loss, muscle atrophy, cardiovascular and metabolic changes and impaired wound healing,...
5.
Shahrour H, Al Fahom S, Al-Massarani G, AlSaadi A, Magni P
J Endocrinol Invest
. 2022 Jan;
45(6):1173-1180.
PMID: 35089541
Purpose: Osteocalcin (OC), an osteoblast-derived regulator of metabolic processes, and circulating early endothelial progenitor cells (EPC, CD34 - /CD133 + /KDR +) expressing OC (OC +) are potential candidates linking...
6.
Tosca E, Terranova N, Stuyckens K, Dosne A, Perera T, Vialard J, et al.
Cancer Chemother Pharmacol
. 2021 Nov;
89(1):117-128.
PMID: 34786600
Purpose: Erdafitinib (JNJ-42756493, BALVERSA) is a tyrosine kinase inhibitor indicated for the treatment of advanced urothelial carcinoma. In this work, a translational model-based approach to inform the choice of the...
7.
Tosca E, Pigatto M, Dalla Costa T, Magni P
Pharm Res
. 2019 Jan;
36(3):38.
PMID: 30635794
Purpose: This work aimed to develop a population PK/PD tumor-in-host model able to describe etoposide effects on both tumor cells and host in Walker-256 tumor-bearing rats. Methods: Etoposide was investigated...
8.
Magni P, Como S, Kamijo A, Montani S
Mar Environ Res
. 2018 May;
139:201.
PMID: 29803322
No abstract available.
9.
Terranova N, Tosca E, Borella E, Pesenti E, Rocchetti M, Magni P
J Theor Biol
. 2018 Apr;
450:1-14.
PMID: 29680449
Host features, such as cell proliferation rates, caloric intake, metabolism and energetic conditions, significantly influence tumor growth; at the same time, tumor growth may have a dramatic impact on the...
10.
Strollo F, Macchi C, Eberini I, Masini M, Botta M, Vassilieva G, et al.
J Endocrinol Invest
. 2018 Mar;
41(11):1267-1273.
PMID: 29532423
Purpose: The "Mars-500 project" allowed to evaluate the changes in psychological/physiological adaptation over a prolonged confinement, in order to gather information for future missions. Here, we evaluated the impact of...